Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, November 20, 2017
[ Mon, Nov 20th 2017
] - WOPRAI
[ Mon, Nov 20th 2017
] - WOPRAI
[ Mon, Nov 20th 2017
] - WOPRAI
[ Mon, Nov 20th 2017
] - WOPRAI
[ Mon, Nov 20th 2017
] - WOPRAI
[ Mon, Nov 20th 2017
] - WOPRAI
[ Mon, Nov 20th 2017
] - WOPRAI
[ Mon, Nov 20th 2017
] - WOPRAI
[ Mon, Nov 20th 2017
] - WOPRAI
Fri, November 17, 2017
[ Fri, Nov 17th 2017
] - WOPRAI
[ Fri, Nov 17th 2017
] - WOPRAI
[ Fri, Nov 17th 2017
] - WOPRAI
[ Fri, Nov 17th 2017
] - WOPRAI
[ Fri, Nov 17th 2017
] - WOPRAI
[ Fri, Nov 17th 2017
] - WOPRAI
[ Fri, Nov 17th 2017
] - WOPRAI
[ Fri, Nov 17th 2017
] - WOPRAI
[ Fri, Nov 17th 2017
] - WOPRAI
[ Fri, Nov 17th 2017
] - WOPRAI
[ Fri, Nov 17th 2017
] - WOPRAI
[ Fri, Nov 17th 2017
] - WOPRAI
[ Fri, Nov 17th 2017
] - WOPRAI
[ Fri, Nov 17th 2017
] - WOPRAI
[ Fri, Nov 17th 2017
] - WOPRAI
Tazeen Ahmad Maintained (ASND) at Strong Buy with Decreased Target to $43 on, Nov 17th, 2017
Tazeen Ahmad of B of A Securities, Maintained "Ascendis Pharma A/S" (ASND) at Strong Buy with Decreased Target from $46 to $43 on, Nov 17th, 2017.
Tazeen has made no other calls on ASND in the last 4 months.
There is 1 other peer that has a rating on ASND. Out of the 1 peers that are also analyzing ASND, 0 agree with Tazeen's Rating of Hold.
This is the rating of the analyst that currently disagrees with Tazeen
- Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $50 on, Friday, September 22nd, 2017
Similar Stocks and Investing Articles
[ Thu, Nov 09th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Fri, Nov 03rd 2017
] - WOPRAI
[ Thu, Oct 19th 2017
] - WOPRAI
[ Thu, Mar 09th 2017
] - WOPRAI
[ Thu, Oct 06th 2016
] - WOPRAI
[ Fri, Aug 23rd 2013
] - WOPRAI
[ Thu, Nov 01st 2012
] - WOPRAI
[ Thu, Nov 01st 2012
] - WOPRAI